GlassScriptPhysician profile
Jack K Oats
NPI 1114921558
$9,116.81
in general payments reported to CMS, 2019-2025
26 companies · $1,751 in 2025
The $1,751 reported for 2025 was more than what 87% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,276 · 2020: $947 · 2021: $1,141 · 2022: $1,231 · 2023: $1,485 · 2024: $1,286 · 2025: $1,751.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,522.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,521.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,578.68 | 2022-2025 | |
| Alcon Vision LLC | $850.20 | 2022-2025 | Clareon, Clareon Panoptix Pro, Tryptyr |
| Glaukos Corporation | $684.60 | 2019-2025 | Idosetr, Photrexa, Photrexa Viscous and Photrexa |
| Aerie Pharmaceuticals, INC. | $645.39 | 2019-2021 | |
| Allergan, INC. | $622.03 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $621.27 | 2019-2023 | |
| Oyster Point Pharma, INC. | $546.32 | 2022-2024 | Tyrvaya, Ryzumvi |
| Mallinckrodt Hospital Products INC. | $503.78 | 2020-2022 | |
| Tarsus Pharmaceuticals, INC. | $435.79 | 2024-2025 | Xdemvy |
| Johnson & Johnson Surgical Vision, INC. | $430.09 | 2019-2024 | Tecnis Iol, Tecnis Iol, Catalys System |
| Bausch & Lomb Americas INC. | $388.48 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Sight Sciences, INC. | $271.47 | 2022-2023 | Tearcare System |
| Eyevance Pharmaceuticals LLC | $246.36 | 2021-2022 | |
| Biotissue Holdings INC. | $215.14 | 2022-2024 | |
| Sun Pharmaceutical Industries INC. | $192.17 | 2020-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $181.45 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $165.19 | 2019-2021 | |
| Carl Zeiss Meditec, INC. | $133.54 | 2019 | |
| Harrow Eye, LLC | $121.79 | 2024-2025 | Vevye |
| Dompe US, INC. | $114.95 | 2022-2025 | Oxervate |
| Mallinckrodt Enterprises LLC | $41.71 | 2019 | |
| Shire North American Group INC | $41.46 | 2019 | |
| Thea Pharma INC. | $24.84 | 2025 | Iyuzeh |
| Tearlab Corp | $24.77 | 2024 | Scoutpro Osmolarity System |
| Horizon Therapeutics Plc | $20.77 | 2023 | Tepezza |
| Rxsight INC | $14.57 | 2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Oats listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.